Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Gourgou-Bourgade S, et al. Among authors: thurlimann b. Ann Oncol. 2015 May;26(5):873-879. doi: 10.1093/annonc/mdv106. Epub 2015 Feb 27. Ann Oncol. 2015. PMID: 25725046 Free article. Review.
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88.
Thürlimann B, Beretta K, Bacchi M, Castiglione-Gertsch M, Goldhirsch A, Jungi WF, Cavalli F, Senn HJ, Fey M, Löhnert T. Thürlimann B, et al. Ann Oncol. 1996 Jul;7(5):471-9. doi: 10.1093/oxfordjournals.annonc.a010635. Ann Oncol. 1996. PMID: 8839901 Free article. Clinical Trial.
Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI.
Goldhirsch A, Gelber RD, Castiglione M, O'Neill A, Thürlimann B, Rudenstam CM, Lindtner J, Collins J, Forbes J, Crivellari D, Coates A, Cavalli F, Simoncini E, Fey MF, Pagani O, Price K, Senn HJ. Goldhirsch A, et al. Among authors: thurlimann b. Ann Oncol. 1997 Aug;8(8):751-6. doi: 10.1023/a:1008220301866. Ann Oncol. 1997. PMID: 9332682 Free article. Clinical Trial.
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
Thürlimann B, Castiglione M, Hsu-Schmitz SF, Cavalli F, Bonnefoi H, Fey MF, Morant R, Löhnert T, Goldhirsch A. Thürlimann B, et al. Eur J Cancer. 1997 Jun;33(7):1017-24. doi: 10.1016/s0959-8049(97)00105-6. Eur J Cancer. 1997. PMID: 9376181 Clinical Trial.
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group.
Thürlimann B, Paridaens R, Serin D, Bonneterre J, Roché H, Murray R, di Salle E, Lanzalone S, Zurlo MG, Piscitelli G. Thürlimann B, et al. Eur J Cancer. 1997 Oct;33(11):1767-73. doi: 10.1016/s0959-8049(97)00283-9. Eur J Cancer. 1997. PMID: 9470830 Clinical Trial.
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK).
Bernhard J, Castiglione-Gertsch M, Schmitz SF, Thürlimann B, Cavalli F, Morant R, Fey MF, Bonnefoi H, Goldhirsch A, Hürny C. Bernhard J, et al. Among authors: thurlimann b. Eur J Cancer. 1999 Jun;35(6):913-20. doi: 10.1016/s0959-8049(99)00028-3. Eur J Cancer. 1999. PMID: 10533471 Clinical Trial.
The Swiss Group for Clinical Cancer Research (SAKK) compared efficacy and toxicity of formestane (250 mg intramuscularly (i.m.) every 2 weeks) versus megestrol acetate (MGA; 160 mg orally daily) as second-line treatment in postmenopausal patients with advanced breast cancer and d …
The Swiss Group for Clinical Cancer Research (SAKK) compared efficacy and toxicity of formestane (250 mg intramuscularly (i.m.) every 2 week …
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.
Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thürlimann B, Holmberg S, Veronesi A, Marini G, Goldhirsch A. Colleoni M, et al. Among authors: thurlimann b. J Clin Oncol. 2000 Feb;18(3):584-90. doi: 10.1200/JCO.2000.18.3.584. J Clin Oncol. 2000. PMID: 10653873
234 results